Samrat Pharmachem (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Samrat Pharmachem Limited |
|||
|
Price: ₹383.40 | ||
| 52 Week Low: ₹320.00 52 Week High: ₹646.00 |
|||
| Market Capital: 111.9 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Samrat Pharmachem Share Price Target For 2024
- 1.1.1: Samrat Pharmachem Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Samrat Pharmachem Share Price Target For 2025
- 1.2.1: Samrat Pharmachem Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Samrat Pharmachem Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Samrat Pharmachem Financial Performance
- 3.0.1: Is Samrat Pharmachem A Good Buy For Long Term?
To predict the Samrat Pharmachem's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Samrat Pharmachem Share Price Target For 2024
The line chart displays the monthly closing prices of Samrat Pharmachem with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Samrat Pharmachem shares in 2024, see the table below.
Samrat Pharmachem Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 404.59 (+5.52%) | Price Action: Aug 2022 Low |
| 2024 Target 2 | 400.1 (+4.34%) | Price Action: 20 Dec 2024 Low |
| 2024 Target 1 | 394.37 (+2.86%) | Price Action: May 2024 High |
| Current Price | 383.40 | Samrat Pharmachem's share price as of 23 Dec 2024 |
| Stop Loss 1 | 378.01 (-1.41%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 2 | 372.78 (-2.77%) | Price Action: Sep 2023 Low |
| Stop Loss 3 | 365.27 (-4.73%) | Price Action: Jun 2022 Low |
Short-Term Technical Outlook
Current Technical Position: Samrat Pharmachem is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹423.36 serves as the nearest technical reference point.
Historical Returns: 3-month: -33.59% | 6-month: +18.7% | 1-year: +15.46%
Samrat Pharmachem Share Price Target For 2025
The line chart displays the monthly closing prices of Samrat Pharmachem with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Samrat Pharmachem shares in 2025, see the table below.
Samrat Pharmachem Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 612.0 (+59.62%) | Price Action: Chart |
| 2025 Target 2 | 600.59 (+56.64%) | Price Action: Chart |
| 2025 Target 1 | 594.64 (+55.09%) | Fibonacci Extension Level 64.90% |
| Current Price | 383.40 | Samrat Pharmachem's share price as of 23 Dec 2024 |
| Stop Loss 1 | 329.81 (-13.98%) | Price Action: Mar 2023 Low |
| Stop Loss 2 | 325.93 (-14.99%) | Price Action: Apr 2024 Low |
| Stop Loss 3 | 320.06 (-16.53%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Samrat Pharmachem is currently trading near its 52-week low of ₹320, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +15.46% | 3-year: +15.18% | 5-year: +313.47%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Samrat Pharmachem Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹383.40 | ||
| 2024 | ₹457.36 | +19.29% | ₹464.22 |
| 2025 | ₹651.96 | +42.54% | ₹699.59 |
| 2026 | ₹788.05 | +20.87% | ₹799.87 |
| 2027 | ₹872.30 | +10.69% | ₹896.20 |
| 2028 | ₹973.41 | +11.59% | ₹988.01 |
| 2029 | ₹1,105.01 | +13.51% | ₹1,121.59 |
| 2030 | ₹1,371.41 | +24.1% | ₹1,486.05 |
| 2031 | ₹1,500.45 | +9.4% | ₹1,522.96 |
| 2032 | ₹1,540.11 | +2.64% | ₹1,682.67 |
| 2033 | ₹1,619.68 | +5.16% | ₹1,879.29 |
| 2034 | ₹1,752.65 | +8.2% | ₹2,075.90 |
| 2035 | ₹2,090.86 | +19.29% | ₹2,272.52 |
| 2036 | ₹2,212.84 | +5.83% | ₹2,246.03 |
| 2037 | ₹2,207.93 | -0.22% | ₹2,469.14 |
| 2038 | ₹2,265.95 | +2.62% | ₹2,665.76 |
| 2039 | ₹2,277.04 | +0.48% | ₹2,862.37 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Samrat Pharmachem Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 111.9 Crore | Market valuation of Samrat Pharmachem's shares. |
| Revenue (TTM) | 310.64 Crore | Total revenue generated by Samrat Pharmachem over the past twelve months. |
| Net Income (TTM) | +16.63 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +7.55% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +9.26% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-22.67% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.31 | Company's total debt divided by total shareholder equity. |
| Total Debt | 20.02 Crore | Sum of Samrat Pharmachem's current & long-term financial obligations. |
| Total Cash | 4.93 Lakh | Total amount of liquid funds available to Samrat Pharmachem. |
Is Samrat Pharmachem A Good Buy For Long Term?
Samrat Pharmachem, with its small market cap and recent revenue dip, presents a moderate risk-to-reward ratio for long-term investment. While its profitability remains stable, the accumulated debt and low cash balance may raise concerns. Despite strong historical returns, the recent downtrend indicates market pressure. Investors seeking higher risk tolerance may consider the opportunity for potential growth, but cautious monitoring is advised given the company's current challenges.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
